Search

Displaying results 4881 - 4890 of 5300 in total
  1. Drug

    Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15716
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB15756
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Influenza B virus B/Washington/02/2019 live (attenuated) antigen

    go.drugbank.com/drugs/DB15758
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16705
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16723
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16725
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  8. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinica...

  9. Drug

    G4460

    go.drugbank.com/drugs/DB06359
    Investigational

  10. Drug

    Alphameprodine

    go.drugbank.com/drugs/DB01499
    ExperimentalIllicit

    Alphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.